RUTHERFORD, N.J., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, announced today that it will present data from a six-month research collaboration with the Memorial Sloan-Kettering Cancer Center, at the Association for Molecular Pathology (AMP) 2013 Annual Conference.
The presentation will provide a poster, a graphical-summarized overview, of the results of the Company's collaborative research and development efforts in creating a urogenital cancer array (UroGenRA™) that could assist in the classification of kidney cancer in a clinical diagnostic setting. The title of the presentation is: Development of an array-comparative genomic hybridization (aCGH)-based algorithm to assist renal tumor subtyping in needle biopsies and resected specimens. The poster will be presented in the solid tumors section on Friday, November 15, 2:30 p.m. to 3:30 p.m. The new kidney cancer diagnostic array was custom-designed by Cancer Genetics.
The annual AMP meeting brings together prominent clinicians, researchers, and institutions in molecular pathology. With over 170 exhibitors, including Abbott Molecular, Roche and Illumina, the AMP Annual Meeting is a prestigious, invitation-only event for the leading research institutions in molecular pathology and clinical medicine.
Panna Sharma, CEO of CGI, commented, "Kidney cancer remains a difficult-to-diagnose disease with an increasing incidence rate and technical challenges at diagnosis. Because choice of therapy depends upon the kidney cancer subtype, as well as the patient's age and comorbidities, there is a need for new tests that can aid in the differentiation of cancer subtypes. Cancer Genetics is at the forefront of developing these tests."
CGI also participated in a multi-institutional research project, sponsored and led by Illumina, and as a result of this study, CGI will be featured in the poster entitled, A multi-institutional study: Evaluation of a novel technique that uses strand specific information to increase accuracy in a next-generation sequencing (NGS) assay to identify somatic DNA variants, which will be presented by Illumina, in the solid tumor section on Saturday, November 16, 9:45 a.m. to 10:45 a.m. (poster number ST73).
The AMP 2013 Annual Meeting takes place November 14-16, 2013, at the Phoenix Convention Center, Phoenix, Arizona. Cancer Genetics personnel will be at booth 322 during the event.
About Cancer Genetics:
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. In addition, the offering is subject to market and other conditions and there can be no assurance as to the estimated proceeds from the offering and the anticipated use of proceeds from the offering. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
CONTACT: Investor Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107 email@example.comSource:Cancer Genetics